• Explore /
  • Poster
  • / Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with <I>BRCA</I>1/2 mutations.

Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.

Abstract Poster

Authors

null

L Rhoda Molife

Royal Marsden Hospital and Institute of Cancer Research, Surrey, United Kingdom

L Rhoda Molife , Joaquin Mateo , Trevor McGoldrick , Matthew Krebs , Yvette Drew , Susana N. Banerjee , Shibani Nicum , Malcolm Ranson , Gordon J. S. Rustin , Cristiana Sessa , Ruth Plummer , Karin Leunen , Michael Friedlander , Helen Swaisland , Wendy Burke , Peter McCormack , Kristine Pemberton , Ilian Tchakov , Stanley B. Kaye , Charlie Gourley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

DNA Repair and Apoptosis

Clinical Trial Registration Number

NCT00777582

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3048)

DOI

10.1200/jco.2012.30.15_suppl.3048

Abstract #

3048

Poster Bd #

13F

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

First Author: Anna F. Farago

First Author: Rana R. McKay

First Author: Ecaterina Elena Dumbrava

First Author: Shalu Pahuja